Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISU302 vs Cerezyme in Type 1 Gaucher Disease
NCT01161914Phase 3Withdrawn
- Sponsor
- ISU Abxis Co., Ltd.
- Start
- Jan 2011
- Primary completion
- Aug 2011
- Modality
- Replacement Enzymes
01
Overview
Phase 3, randomised, double-blind trial of imiglucerase in Gaucher disease type 1 (GD1) (2 arms), sponsored by ISU Abxis Co., Ltd. Primary endpoint: Change in splenic volume compared to baseline at 1 year. Planned start Jan 2011; status: withdrawn.
02
Drugs
imiglucerase
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on NCT01161914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01161914.